Myriad Genetics (DB:MYD) - Stock Price, News & Analysis

MYD Stock Overview

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally.

About the company

MYD fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	1/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Rewards

Trading at 57.3% below our estimate of its fair value

Revenue is forecast to grow 7.37% per year

Trading at good value compared to peers and industry

Risk Analysis

Shareholders have been diluted in the past year

Myriad Genetics, Inc. Competitors

Biotest

XTRA:BIO3

€1.4b

MorphoSys

XTRA:MOR

€2.5b

Formycon

XTRA:FYB

€682.6m

Heidelberg Pharma

XTRA:HPHA

€139.8m

Price History & Performance

Summary of all time highs, changes and price drops for Myriad Genetics
Historical stock prices
Current Share Price	US$17.20
52 Week High	US$22.00
52 Week Low	US$13.20
Beta	1.98
1 Month Change	-15.69%
3 Month Change	-11.79%
1 Year Change	-14.85%
3 Year Change	-31.88%
5 Year Change	-39.22%
Change since IPO	612.95%

Recent updates

Shareholder Returns

	MYD	DE Biotechs	DE Market
7D	-6.0%	-5.1%	-2.0%
1Y	-14.9%	-21.1%	-0.3%

Return vs Industry: MYD exceeded the German Biotechs industry which returned -21.1% over the past year.

Return vs Market: MYD underperformed the German Market which returned -0.3% over the past year.

Price Volatility

Is MYD's price volatile compared to industry and market?
MYD volatility
MYD Average Weekly Movement	6.8%
Biotechs Industry Average Movement	5.0%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.0%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: MYD's share price has been volatile over the past 3 months.

Volatility Over Time: MYD's weekly volatility (7%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1991	2,700	Paul Diaz	www.myriad.com

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.

Myriad Genetics, Inc. Fundamentals Summary

How do Myriad Genetics's earnings and revenue compare to its market cap?
MYD fundamental statistics
Market cap	€1.57b
Earnings (TTM)	-€247.16m
Revenue (TTM)	€707.03m

2.2x

P/S Ratio

-6.4x

P/E Ratio

Is MYD overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
MYD income statement (TTM)
Revenue	US$753.20m
Cost of Revenue	US$236.20m
Gross Profit	US$517.00m
Other Expenses	US$780.30m
Earnings	-US$263.30m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-2.91
Gross Margin	68.64%
Net Profit Margin	-34.96%
Debt/Equity Ratio	4.9%

How did MYD perform over the long term?

See historical performance and comparison

MYD Stock Overview

Rewards

Risk Analysis

Myriad Genetics, Inc. Competitors

XTRA:BIO3

€1.4b

XTRA:MOR

€2.5b

XTRA:FYB

€682.6m

XTRA:HPHA

€139.8m

Price History & Performance

Recent News & Updates

Myriad Genetics, Inc. Updates Revenue Guidance for the Fiscal Year 2024

Myriad Genetics, Inc. Provides Revenue Guidance for the First Quarter 2024

Full year 2023 earnings released: US$3.18 loss per share (vs US$1.39 loss in FY 2022)

Myriad Genetics, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Myriad Genetics, Inc. Appoints George Daneker as President and Chief Clinical Officer of Oncology, Effective March 18, 2024

Myriad Genetics, Inc. (NasdaqGS:MYGN) agreed to acquire Select assets of Intermountain Precision Genomics.

Recent updates

Myriad Genetics, Inc. Updates Revenue Guidance for the Fiscal Year 2024

Myriad Genetics, Inc. Provides Revenue Guidance for the First Quarter 2024

Full year 2023 earnings released: US$3.18 loss per share (vs US$1.39 loss in FY 2022)

Myriad Genetics, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Myriad Genetics, Inc. Appoints George Daneker as President and Chief Clinical Officer of Oncology, Effective March 18, 2024

Myriad Genetics, Inc. (NasdaqGS:MYGN) agreed to acquire Select assets of Intermountain Precision Genomics.

Myriad Genetics, Inc. Announces Chief Financial Officer Changes

Myriad Genetics, Inc. has completed a Follow-on Equity Offering in the amount of $109.999996 million.

New minor risk - Shareholder dilution

Myriad Genetics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Myriad Genetics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Myriad Genetics, Inc. Provides Financial Guidance for 2023 and 2024

Third quarter 2023 earnings released: US$0.75 loss per share (vs US$0.43 loss in 3Q 2022)

Myriad Genetics, Inc. Appoints Samraat S. Raha as Chief Operating Officer, Effective as of December 11, 2023

Myriad Genetics Appoints Sam Raha as Chief Operating Officer, Effective December 11, 2023

Myriad Genetics, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Bernstein Litowitz Berger & Grossmann LLP Proposes Settlement of Class Action Involving Persons Who Purchased or Acquired Myriad Genetics, Inc. Common Stock

Insufficient new directors

Myriad Genetics Announces Enhancements to the Genesight® Test to Personalize Mental Health Medication Treatment Decisions Based on Smoking Status

Myriad Genetics, Inc. Provides Earnings Guidance for the Year 2023

Second quarter 2023 earnings released: US$1.42 loss per share (vs US$0.17 loss in 2Q 2022)

Myriad Genetics, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Myriad Genetics, Inc. Announces Inclusion of Breast Density to Myrisk(R) with Riskscore(R) Breast Cancer Risk Assessment

Myriad Genetics, Inc. Appoints Adam Brufsky as Scientific Advisor

Myriad Genetics, Inc. Revises Earnings Guidance for the Full Year of 2023

First quarter 2023 earnings released: US$0.67 loss per share (vs US$0.26 loss in 1Q 2022)

Full year 2022 earnings released: US$1.39 loss per share (vs US$0.35 loss in FY 2021)

Myriad Genetics, Inc. Hires Senior Leaders to Advance Commercial Growth Plans

Myriad Genetics, Inc. announces Patient Outcomes Study Shows RiskScore Leads to More Accurate Breast Cancer Risk Prediction than Standard-of-Care Risk Model

High number of new directors

Myriad Genetics Announces Urosuite™, an Industry-First Suite of Genetic Tests for Prostate Cancer, Giving Urologists Access to Timely, Data-Driven Medical Information

Third quarter 2022 earnings released: US$0.43 loss per share (vs US$0.31 profit in 3Q 2021)

Myriad Genetics, Inc. (NasdaqGS:MYGN) acquired Gateway Genomics, LLC for approximately $110 million.

Myriad Genetics, Inc. Elects Paul M. Bisaro as New Board Member

High number of new directors

Myriad Genetics, Inc. to Report Q3, 2022 Results on Nov 01, 2022

Myriad Genetics Receives Expanded Coverage in Japan for Use of BRACAnalysis® Diagnostic System as a Companion Diagnostic for Lynparza® in Early-Stage Breast Cancer

Second quarter 2022 earnings released: US$0.17 loss per share (vs US$0.061 loss in 2Q 2021)

Myriad Genetics, Inc. Provides Earnings Guidance for the Year 2022

Myriad Genetics, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Myriad Genetics, Inc. Announces the Resignation of Dennis Langer as Director

Myriad Genetics, Inc. Announces Executive Changes

Myriad Genetics Showcases Advancements in Precision Medicine with Recent Oncology Portfolio Expansion and New Data Presentations at ASCO 2022

First quarter 2022 earnings released: US$0.26 loss per share (vs US$0.52 loss in 1Q 2021)

Myriad Genetics, Inc. Provides Earnings Guidance for the Fiscal Year 2022

High number of new directors

Myriad Genetics, Inc., Annual General Meeting, Jun 02, 2022

Myriad Genetics, Inc. Settles the Qui Tam Lawsuit with STF, LLC

Forecast to breakeven in 2024

Myriad Genetics, Inc. Reiterates Earnings Guidance for the Fiscal Year 2022

Investor sentiment deteriorated over the past week

Myriad Genetics, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Myriad Genetics, Inc. Provides Earnings Guidance for the Year 2022

Laboratory Corporation of America Holdings (NYSE:LH) completed the acquisition of Autoimmune’s Vectra Testing Business from Myriad Genetics, Inc. (NasdaqGS:MYGN).

Independent Chair of the Board recently sold €529k worth of stock

Myriad Genetics, Inc. Reports Goodwill and Long-Lived Asset Impairment Charges for the Second Quarter Ended June 30, 2021

Myriad Genetics, Inc. Launches New Version of its MyRisk Hereditary Cancer Test

Q2 Solutions LLC completed the acquisition of Myriad RBM, Inc. from Myriad Genetics, Inc. (NasdaqGS:MYGN).

Q2 Solutions LLC signed a definitive agreement to acquire Myriad RBM, Inc. from Myriad Genetics, Inc. (NasdaqGS:MYGN) for approximately $200 million.